Iovance Biotherapeutics (GB:0JDK)
NASDAQ:0JDK
0JDK Stock Chart & Stats
$3.90
-$0.20(-2.69%)
At close: 4:00 PM EST
$3.90
-$0.20(-2.69%)
Day’s Range― - ―
52-Week Range$1.68 - $5.69
Previous CloseN/A
Volume15.47K
Average Volume (3M)141.14K
Market Cap
$1.69B
Enterprise Value$1.32B
Total Cash (Recent Filing)$313.44M
Total Debt (Recent Filing)$46.78M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Aug 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding446,502,400
10 Day Avg. Volume169,208
30 Day Avg. Volume141,142
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.40
Price to Sales (P/S)3.70
P/FCF Ratio-2.90
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue4.61
Enterprise Value/Gross Profit4.02
Enterprise Value/Ebitda-4.03
Forecast
1Y Price Target
$9.80Price Target Upside151.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$359.76M
Bulls Say, Bears Say
Bulls Say
Commercial Momentum & Revenue GrowthSustained, high-single-quarter revenue growth driven by Amtagvi adoption signals durable commercial traction: rising physician awareness, larger monthly uptake, and tight guidance indicate expanding referral and treatment volumes that should support revenue expansion over the next 2–6 months.
Manufacturing Control & CapacityBringing manufacturing in-house and completing modular facility upgrades materially reduces supply risk, supports higher throughput and consistency, and improves long-term unit economics. This structural capability underpins scalable commercialization and international rollouts over the medium term.
Improved Cost Discipline & Multi-Year RunwayConsecutive R&D reductions and explicit cash runway into 2028 reflect stronger cost control and a multi-year financing buffer. That gives management time to execute commercialization, registrational trials, and margin improvement initiatives without immediate capital pressure.
Bears Say
High Cash BurnPersistent, large negative operating and free cash flow implies ongoing reliance on external financing or rapid margin expansion to sustain growth. This structural cash outflow pressure limits strategic flexibility and raises dilution or funding-risk over the next several quarters absent material operating improvement.
Sustained Net LossesSubstantial multi-quarter net losses are consuming shareholder capital and producing deeply negative margins. Until the business moves toward break-even, ongoing losses will depress returns on invested capital and constrain reinvestment or dividend optionality for the foreseeable 2–6 month horizon.
Regulatory & Enrollment Execution RiskKey near-term value drivers (registrational readouts and accelerated approvals, plus timely enrollment for sarcoma/NSCLC programs) are execution-dependent. Delays or negative regulatory outcomes could materially postpone launches and peak sales, creating sustained upside risk to the commercial thesis.
Iovance Biotherapeutics News
0JDK FAQ
What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest share price was $1.68 and its highest was $5.69 in the past 12 months.
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is $1.69B.
When is Iovance Biotherapeutics’s upcoming earnings report date?
Iovance Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 61 days.
How were Iovance Biotherapeutics’s earnings last quarter?
Iovance Biotherapeutics released its earnings results on May 07, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.154 by -$0.036.
Is Iovance Biotherapeutics overvalued?
According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued.
Does Iovance Biotherapeutics pay dividends?
Iovance Biotherapeutics pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Iovance Biotherapeutics dividends here
What is Iovance Biotherapeutics’s EPS estimate?
Iovance Biotherapeutics’s EPS estimate is -0.13.
How many shares outstanding does Iovance Biotherapeutics have?
Iovance Biotherapeutics has 446,502,400 shares outstanding.
What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
Iovance Biotherapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.154. Following the earnings report the stock price went down -11.794%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics?
Currently, no hedge funds are holding shares in GB:0JDK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.80 (151.28% Upside)
$9.80 (151.28% Upside)
Blogger Sentiment
Bullish
GB:0JDK Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
139.34%
12-Months-Change
Fundamentals
Return on Equity
-50.17%
Trailing 12-Months
Asset Growth
-4.25%
Trailing 12-Months
Company Description
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
0JDK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful operational progress: high single-quarter revenue growth (~45% YoY), robust Amtagvi demand (+38% YoY), tighter Q2/full-year guidance, expanded manufacturing control, R&D cost reductions, extended cash runway into 2028, and encouraging early clinical signals (e.g., 40% ORR in serous endometrial cancer). Near-term headwinds include a one-time facility-related margin hit (Q1 gross margin ~41%), some quarter-to-quarter revenue volatility in Proleukin, continued use of ATM financing, and the usual clinical/regulatory and enrollment execution risks. Overall, the positives—notably accelerating commercial traction, pipeline advances, and improved cost discipline—substantially outweigh the listed challenges.View all GB:0JDK earnings summaries0JDK Stock 12 Month Forecast
Average Price Target
$9.80
▲(151.28% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Vir Biotechnology
―
Immatics
―
Nuvation Bio
―
Amylyx Pharmaceuticals Inc
―
Options Prices
Currently, No data available
---